Key Highlights
● Alnylam Pharmaceuticals closed at $231.83 on October 16, trading below the analyst target.
● The consensus 12-month price target is $368.71, implying about 59.0% upside.
● Analysts are split 23 Buy, 7 Hold, and 0 Sell on the stock.
● Targets range from $250 to $536 across 30 analysts.
Alnylam Pharmaceuticals (NASDAQ:ALNY), a Nasdaq-listed company, closed at $231.83 on October 16, 2026 (Friday October 16, 2026). It is a member of the Nasdaq-100. The consensus analyst price target is $368.71, which suggests potential upside of about 59.0% from the latest close if the consensus proves accurate. The RNAi therapeutics company has drawn attention as brokers have trimmed targets ahead of its third-quarter results.
What Is the Latest Analyst Price Target?
According to market data, 30 analysts cover the stock, with a mean target of $368.71, a median of $350, a high of $536 and a low of $250. Data date: October 14, 2026 (ratings October 2026). The consensus rating is Buy. Targets range from $250 to $536. Recent actions include Wells Fargo reiterating Hold with $253 (from $256) on October 14, 2026, Citi reiterating Buy with $320 (from $340) the same day, Truist initiating at Buy with $354 on 14 October, Barclays maintaining Buy with $450 on 13 October and Bank of America reiterating Buy on 9 October. Other reports note UBS assuming coverage at Buy with $354, down from $550, and JPMorgan trimming to $369 from $375.
What Are Analysts Saying?
The rating split is 23 Buy (17 Strong Buy, 6 Buy), 7 Hold, 0 Sell. Sentiment is strongly positive, with 23 of 30 analysts rating the shares Buy or Strong Buy and none Sell. Supportive analysts highlight rapid commercial growth: trailing-twelve-month revenue is $4.80 billion, up 95.1%, with net income of $774.71 million. The cautious camp, including Wells Fargo and Jefferies (Hold, $260), points to valuation and expectations.
What Could Help the Stock Reach the Price Target?
If the consensus proves accurate, further growth in sales of its marketed medicines such as AMVUTTRA, progress in the pipeline and profit expansion could narrow the gap between the share price and the average target. Positive third-quarter results would be an important test. The consensus target suggests there is room for recovery, but this depends on delivery and market conditions.
What Could Prevent the Stock Reaching the Target?
Biotechnology shares can be volatile. The recent run of target cuts suggests analysts have become more cautious, and pipeline setbacks, pricing pressure, competition in transthyretin amyloidosis or slower-than-expected launches could keep the shares below the consensus level. The mean target of $368.71 also sits well above the $250 low, indicating wide disagreement.
What Should Investors Watch Next?
Alnylam has said it will webcast its third-quarter 2026 results call, with results due on October 29, 2026. Investors may watch revenue growth, guidance and clinical updates. Alnylam will report third-quarter 2026 results on October 29, 2026 and has launched an AMVUTTRA educational initiative.
A Target Built on Faith
The consensus target of $368.71 implies about 59.0% above the $231.83 close on October 16, 2026, but analyst forecasts can change and are not guarantees of future performance.






Please wait processing your request...